Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.

Integrated Symposia


For the full programme of the Integrated Symposia please click here

13:15 – 15:15

Pfizer 

Revising the paradigm: the Importance of adult vaccination against respiratory diseases


13:15 – 14:15

Copan

The challenges of managing the COVID-19 pandemic from pre-analytic to diagnosis


13:15 – 14:15

Thermo Fisher

Viruses mutate, and SARS-CoV-2 is no exception. Emerging mutation surveillance and confirmation


13:15 – 15:15

Janssen Pharmaceuticals

Spotlight on COVID-19: where are we now?


14:15 – 15:15

Valneva

Developing new vaccines to protect against infectious diseases at home and abroad


15:15 – 16:15

Abbott

How the pandemic changed the pathway of diagnosis of infectious diseases: rapid diagnostic solutions for COVID-19


16:15 – 18:15

Sanofi Pasteur

Importance of influenza vaccination in the COVID-19 environment


16:15 – 18:15

Menarini

Superbugs, Susceptibility & Stewardship: with more antibiotics available for multidrug-resistant Gram-negative bacterial infections, what's holding us back?


16:15 – 18:15

AstraZeneca

Deciphering the data: clinical impact of vaccines and monoclonal antibodies for COVID-19


16:15 – 17:45

Pfizer

The role of patients in infectious disease research: from study participants to scientific partners


08:30 – 09:30

Seegene Inc.

An innovative approach to infection control


08:30 – 10:00

Sanofi Pasteur

Surviving invasive meningococcal disease (IMD): the long-term impact and future preventive perspectives


08:30 – 10:30

Merck Sharp & Dohme

Gram-negative infections in the post-COVID world: what are we left with?


09:00 – 10:30

Quidel Ireland Ltd.

Novel rapid diagnostic solutions aiming to improve the diagnosis of C. difficile infections and respiratory infections


13:15 - 14:45

Merck Sharp & Dohme

Adult pneumococcal vaccination: evidence to inform optimal policy for at-risk groups and the role of polysaccharide vaccines


13:15 – 15:15

Shionogi & Co., Ltd.

Taking a look inside the Trojan Horse


13:15 – 15:15

F2G Ltd.

Are we ready for personalised medicine in the treatment of mould infections?


13:15 – 14:15

Pfizer

COVID-19: out of adversity comes learnings


16:15 – 18:15

Bruker Daltonics GmbH & Co. KG

Changing Microbiology: enhancing technologies to address today’s critical diseases


16:15 – 18:15

Pfizer

Piecing together the patient puzzle: navigating the MDR Gram-negative infection treatment paradigm


16:15 - 17:45

Gilead Europe Sciences Ltd.

The role and timing of antiviral therapy in the treatment of COVID-19


16:15 – 17:45

bioMérieux SA

Syndromic testing, new standard of care


08:30 – 10:30

Menarini

Easing patient management and improving patient outcomes with innovative molecules


09:30 – 10:30

Insmed

NTM Pulmonary disease: do we need to rethink our management strategies?


08:30 - 10:30

Merck Sharp & Dohme

Changing the paradigm of COVID-19 management: early diagnosis and treatment in non-hospitalised patients


13:15 – 15:15

F.Hoffmann-La Roche

Latest advances in diagnostic and treatment solutions for the COVID-19 pandemic: overcoming challenges in a rapidly evolving environment


13:15 – 15:15

Gilead Europe Sciences Ltd.

New frontiers in invasive fungal diseases


13:15 – 15:15

Pfizer

Treating invasive mould disease in an era of complex epidemiology and patient needs


13:15 – 15:15

Advanz Pharma

Place in therapy of contemporary lipoglycopeptides and cephalosporins in an evolving environment


16:15 – 18:15

DiaSorinSA

Diagnosis and immune response of SARS-CoV-2 infection


16:15 – 18:15

Pfizer

What are the treatment options for CAP and cSSTI in 2021?


16:15 – 18:15

Beckman Coulter

The clinical microbiology lab in 2021: resistance detection and more


16:15 - 17:15

GSK

Monoclonal antibodies (mAbs) in the treatment of COVID-19: what have we learnt?


17:15 - 18:15

GSK

AMR and the need for innovation: where we are now? And where do we need to be?


16:15 – 18:15

Accelerate Diagnostics Inc.

Bacteremia diagnostics in a brave new viral world: clinical microbiology and patient management considerations


09:30 – 10:30

T2 Biosystems

The crucial role of rapid diagnostics in the early detection of secondary bacterial and fungal infections complicating COVID-19


13:15 – 15:15

Qiagen

Syndromic diagnostics: better timing and better insights to improve patient care in COVID-19 and beyond


16:15 – 18:15

Qiagen

Enabling critical testing needs in clinical microbiology: innovative, random-access molecular diagnostic solutions to address pandemic and post-pandemic needs